Mounjaro is a new medication developed by Eli Lilly that contains the active ingredient tirzepatide. It was originally designed to help people with type 2 diabetes manage their blood sugar levels. Mounjaro is administered as a once-weekly injection using a self-injection pen, typically into the abdomen, thigh, or upper arm. In the UK, tirzepatide (Mounjaro) has been approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA).
Besides helping with blood sugar, Mounjaro has also been found to be very effective at helping people lose weight. This is why you might have heard it called a "weight loss jab" in the media.
Mounjaro is like a "twin hormone" medicine. It acts like two natural gut hormones, GLP-1 and GIP. These hormones help control blood sugar and appetite.
Both are effective weekly injections. Semaglutide works on GLP-1 while Mounjaro works on both GLP-1 and GIP. Studies suggest Mounjaro may lead to slightly more weight loss on average. But choice of drug depends on a number of factors and is very individual.
Side Effects and Safety:
Common side effects are usually mild stomach issues (nausea, vomiting, etc.) that often improve over time. Because it affects appetite, you'll feel less hungry. If you take other diabetes medicines, your doctor might adjust doses to prevent low blood sugar.
Serious side effects are rare, but contact a doctor immediately for severe tummy pain, persistent vomiting, allergic reactions, or worrying mood changes.
Important Note: Mounjaro works best with healthy eating and exercise. If you stop Mounjaro, appetite and weight can return if lifestyle changes aren't maintained.
Check our healthcare support page to see if Mounjaro could be a suitable option for you based on your health needs and the latest criteria.
1. How is Mounjaro administered?Mounjaro is given as a once-weekly injection. Your healthcare provider will guide you on the correct dosage and administration technique.
2. Can I use Mounjaro if I’m pregnant or breastfeeding?No, tirzepatide is not recommended during pregnancy or breastfeeding, as its safety in these situations has not been established. If you are planning to conceive or are breastfeeding, discuss alternative options with your doctor.
3. How long does it take to see results with Mounjaro?While individual results vary, many users begin noticing changes within a few weeks. Maximum benefits are typically observed after several months of consistent use, alongside dietary and lifestyle adjustments.
A groundbreaking clinical trial has revealed that Mounjaro (tirzepatide) leads to greater weight loss than its rival Wegovy (semaglutide), offering new hope for people struggling with obesity.
The study, presented at the European Congress on Obesity and published in the New England Journal of Medicine, compared the two most talked-about weight-loss injections. Over 72 weeks, participants taking Mounjaro lost an average of 20% of their body weight, compared to 14% for those on Wegovy. That’s a significant difference, especially for those with a lot of weight to lose.
Both Mounjaro and Wegovy help people feel full, reducing appetite and encouraging the body to burn stored fat. The key difference is that Wegovy mimics one appetite-control hormone, while Mounjaro targets two, which may explain its superior results.
Both Mounjaro and Wegovy are available for weight management in the UK through both the NHS and private clinics. Here’s what you need to know about who can access them and how.
Both medications are available on the NHS, but only for people who meet specific criteria:
For those seeking treatment privately, the requirements are less strict:
Customers seeking access to weight loss treatments like Mounjaro and Wegovy can conveniently receive private prescriptions through online clinics such as SheMed Healthcare. SheMed specializes in providing healthcare services tailored for women, including a dedicated weight loss programme.
Here is a breakdown of the programme's pricing:
This major trial confirms Mounjaro's significant edge over Wegovy, demonstrating superior weight loss and better health outcomes for individuals with obesity. Both medications represent powerful advancements in weight management and are available in the UK via NHS and private pathways, offering promising new options for those seeking effective medical treatment. If you have any questions about these medications or weight loss options, please visit the SheMed Support website for more information.
Many individuals find themselves in a constant battle with their weight, despite maintaining active lifestyles and trying various diets and exercise routines. Stubborn pounds can feel impossible to lose, leading to feelings of frustration and defeat. If you've experienced the seemingly endless cycle of trying to shed weight without lasting success, you understand this challenge. However, recent advancements offer a potential breakthrough. GLP-1 medications, a class of drugs that mimic natural hormones to help regulate hunger and insulin, have shown promising results for weight loss. When combined with healthy lifestyle changes – including a balanced diet, regular physical activity, sufficient sleep, and stress management – these medications can create a powerful synergistic effect, not only aiding in weight loss but also supporting overall metabolic health.
GLP-1 receptor agonists work by mimicking a natural hormone in your body that helps regulate appetite, insulin, and digestion. When you take a GLP-1 medication like Mounjaro, Wegovy, or Ozempic, it activates GLP-1 receptors in the brain and gut. This leads to three main effects that support weight loss:
By targeting both biological and behavioural aspects of eating, GLP-1 medications make it easier to create a calorie deficit — the foundation of sustainable weight loss.
GLP-1 medications such as Wegovy and Mounjaro are approved for weight management when used alongside lifestyle changes like a reduced-calorie diet and regular exercise.
Whether prescribed via the NHS or privately, GLP-1 medications should always be part of a structured, long-term weight management plan, not used in isolation.
A balanced diet is a cornerstone of any weight loss journey, and it's particularly important when combining it with GLP-1 therapy. GLP-1 medications can help reduce appetite and regulate blood sugar levels, but diet plays a crucial role in achieving and maintaining weight loss.
A well-rounded, nutrient-dense diet is essential for weight loss and long-term health. Research shows that diets rich in whole foods, fibre, and lean proteins, while limiting processed sugars and unhealthy fats, can aid in sustainable weight management.
In the Diabetes Prevention Program (DPP), participants who combined a low-calorie, low-fat diet with physical activity and behavioural counselling were able to lose 5-7% of their body weight, significantly reducing their risk of developing type 2 diabetes. This highlights the importance of diet in weight management, especially when combined with GLP-1 therapy.
GLP-1 medications naturally help with appetite suppression, but pairing them with caloric restriction such as reducing intake by 500–750 calories per day can accelerate weight loss. Clinical studies suggest that even modest reductions in caloric intake lead to significant weight loss over time. The STEP 1 Trial demonstrated that semaglutide (a GLP-1 medication) combined with caloric restriction resulted in a 15% average weight loss over 68 weeks.
A balanced intake of macronutrients is key to supporting energy levels and maintaining muscle mass while losing fat. Protein is particularly important for preserving lean mass during weight loss.
Mindful eating helps women tune into their hunger cues and reduce overeating. Studies show that mindfulness can reduce emotional eating and improve long-term weight management. A meta-analysis found that mindfulness-based interventions improved weight loss outcomes and sustained weight maintenance in participants over a year.
Physical activity is vital for supporting the effects of GLP-1 therapy and enhancing weight loss. Regular exercise not only helps burn calories but also improves insulin sensitivity, supports cardiovascular health, and boosts mental well-being.
The government recommends that adults engage in at least 150 minutes of moderate-intensity aerobic activity (e.g., brisk walking, cycling) or 75 minutes of vigorous-intensity aerobic activity (e.g., running, swimming) each week, in addition to strength training exercises twice a week. In the DPP trial, participants who engaged in physical activity and dietary changes lost an average of 7% of their body weight, while also improving their insulin sensitivity.
Combining different types of exercise maximises benefits:
Starting small and gradually increasing exercise intensity is key to building consistency. Here are a few tips:
Sleep is a powerful yet often overlooked aspect of weight management. Quality sleep is essential for hormonal regulation, appetite control, and energy balance.
Chronic sleep deprivation can disrupt hormones like ghrelin (hunger hormone) and leptin (satiety hormone), leading to increased appetite and cravings for unhealthy foods. Women, particularly during perimenopause and menopause, often experience disrupted sleep patterns, which can make weight loss more challenging. A study showed that people who slept less than 7 hours per night had higher levels of ghrelin and lower levels of leptin, which can contribute to weight gain.
A study from The Sleep Research Society found that women who consistently get 7-9 hours of sleep per night are more likely to maintain a healthy weight compared to those who sleep less.
Stress can have a profound impact on weight loss. High stress levels can trigger the release of cortisol, a hormone that promotes fat storage, especially in the abdominal area. Managing stress is therefore crucial for successful weight loss.
Incorporating stress management practices can improve overall well-being and support weight loss:
While GLP-1 medications offer significant benefits for weight loss, women may encounter a variety of challenges during their weight loss journey. These challenges can range from side effects to difficulties adhering to lifestyle changes. Understanding these obstacles and implementing effective solutions can significantly enhance the success of GLP-1 therapy.
One of the most common challenges with GLP-1 medications is gastrointestinal distress, including nausea, vomiting, diarrhoea, and abdominal pain. These side effects occur because GLP-1 medications slow gastric emptying, which helps control hunger but can also lead to digestive discomfort.
In clinical trials, semaglutide has shown that around 30-40% of patients experience nausea during the initial weeks of treatment, with 2-10% reporting vomiting. A study found that 1 in 5 patients discontinued treatment due to side effects, though many cases were mild and resolved over time.
Eating smaller, more frequent meals and avoiding high-fat, greasy foods can help manage nausea. A low-fat diet is also advised as fat can exacerbate gastrointestinal issues. A clinical study on tirzepatide found that following low-fat dietary modifications reduced nausea and improved adherence to the medication regimen.
Maintaining a healthy, balanced diet while undergoing GLP-1 therapy can be difficult, especially for those with busy lifestyles or a history of emotional eating. While GLP-1 medications help curb appetite, adhering to a calorie-controlled, nutrient-dense diet is key for long-term weight loss success. In the STEP 2 trial, patients who adhered to a reduced-calorie diet experienced an average weight loss of 14.9% with semaglutide, compared to a 3.3% loss in the placebo group. However, participants who struggled with diet adherence showed less weight loss, underlining the importance of nutrition.
Importance of Meal Planning and Preparation
Setting realistic dietary goals, planning meals ahead, and incorporating high-protein, fibre-rich foods can improve adherence. Working with a registered dietitian to create personalised meal plans helps ensure that weight loss goals align with nutritional needs. A study showed that meal planning with a focus on protein-rich and low-glycemic index foods significantly enhances weight loss outcomes for those using GLP-1 medications.
Exercise is a key component of weight loss, yet many women find it difficult to incorporate regular physical activity into their daily routines. Factors such as fatigue (a common side effect of GLP-1 therapy), lack of time, or low motivation can make it hard to stay consistent with exercise. In the STEP 4 trial, patients who combined semaglutide with regular physical activity (including cardiovascular and strength training exercises) achieved a significantly greater weight loss of 15.1% compared to 5.4% in the placebo group, demonstrating the synergistic effects of exercise and medication.
Start with moderate-intensity activities, such as walking, and gradually progress to more intense strength training and cardiovascular exercises. Building a routine that includes enjoyable activities increases adherence and long-term sustainability. The Diabetes Prevention Program study found that moderate-intensity exercise, such as brisk walking, for 150 minutes per week significantly improved weight loss and metabolic health, especially when combined with dietary changes.
Weight loss journeys are often hindered by psychological challenges such as stress, anxiety, and emotional eating, which can increase the risk of weight re-gain. Women, in particular, may face challenges related to body image, societal pressures, and mood disorders that impact their progress.
A study found that cognitive-behavioural therapy (CBT) was an effective strategy for improving emotional eating and dietary adherence. Women who underwent CBT while using GLP-1 medications had significantly better outcomes in managing stress and weight loss compared to those without psychological support.
Importance of Stress Management and Therapy
Implementing mindfulness techniques, such as deep breathing, yoga, or meditation, can help manage stress. Cognitive-behavioural therapy (CBT) has been shown to reduce emotional eating and improve adherence to both medication and lifestyle changes.
A study on stress and weight loss published in The Journal of Clinical Endocrinology and Metabolism demonstrated that participants who combined CBT with GLP-1 therapy lost significantly more weight and experienced better long-term maintenance compared to those who did not receive mental health support.
After achieving initial weight loss with GLP-1 therapy, some women may experience weight regain. This is a common challenge in weight management, especially when GLP-1 medications are discontinued or when lifestyle changes are not maintained.
In the STEP 4 trial, semaglutide showed that weight regain occurred when treatment was paused, with participants gaining back about 2.4 kg on average after discontinuation. This highlights the importance of long-term adherence to medication and lifestyle modifications.
Long-term Adherence
To prevent weight re-gain, continue using GLP-1 medications as prescribed, along with regular follow-ups and ongoing consultation with healthcare professionals to monitor progress. Combining ongoing medication use with sustainable diet and exercise habits is essential for maintaining weight loss. The SUSTAIN trials demonstrated that patients who continued semaglutide over the long term experienced significantly lower rates of weight re-gain compared to those who stopped treatment.
Combining GLP-1 medications with sustainable lifestyle changes is a holistic approach to weight loss that maximises your chances for long-term success. While GLP-1 therapies can curb appetite and support fat loss, it’s the addition of mindful eating, regular physical activity, and mental health strategies that will truly help you maintain the results. The key to success lies in setting realistic goals, tracking your progress, and seeking support when needed.
Remember, weight loss is a journey, not a race, and every small step you take towards a healthier lifestyle is a step towards a brighter, more energised you. With the right support, patience, and commitment to both your treatment plan and lifestyle changes, you’ll not only lose weight but gain confidence and improved overall well-being.
If you are looking for personalised guidance, check out details of SheMed weight loss programme here.
Frequently Asked Questions (FAQs)
1. Can I rely on GLP-1 medications alone for weight loss?
While GLP-1 medications like semaglutide and tirzepatide can significantly support weight loss, they work best when combined with a healthy diet and regular physical activity. These medications help reduce appetite and slow gastric emptying, but lifestyle changes help you maintain a healthy weight and prevent weight regain.
2. Will combining exercise with GLP-1 therapy help me lose more weight?
Yes! Studies have shown that combining exercise with GLP-1 therapy can lead to enhanced weight loss. In the STEP 4 trial, patients who participated in exercise routines alongside semaglutide had greater weight loss results than those on medication alone. Cardiovascular exercises and strength training are particularly effective.
3. What if I experience side effects from GLP-1 medications?
Side effects like nausea and diarrhoea are common when starting GLP-1 therapy but usually subside with time. To reduce side effects, stay hydrated, eat smaller meals, and avoid fatty foods. If symptoms persist, speak to your healthcare provider for tailored advice or to adjust your dosage.
Starting a weight loss journey can feel a bit like standing at the bottom of a mountain. It’s exciting, full of possibility but let’s be honest, it can also be pretty overwhelming. Whether you’re hoping to drop a few pounds or make bigger lifestyle changes, one thing can make all the difference: tracking your progress.
Now, you might be wondering, “Isn’t stepping on the scale enough?” Not quite. Tracking is about so much more than just the number you see on your bathroom scale. It’s about understanding how your body reacts to what you eat, how you move, and how you live. When done right, it can help you stay motivated and make smarter choices.
If you're with SheMed, weekly weigh-ins are a required part of the programme — our proctors check and record your weight before each GLP-1 injection to keep you on track. And if you’re with another provider, it’s still worth building in your own consistent weekly check-ins. That regular feedback loop is powerful. Let’s dive into why tracking matters, how it can empower you, and the best ways to go about it.
“Why bother tracking if the scale isn’t budging?” Great question. The truth is, there’s a lot happening behind the scenes when you’re trying to lose weight things the scale doesn’t show.
Tracking doesn’t have to be complicated. In fact, the best methods are often the simplest.
Once a week, same day, same time that’s the sweet spot. Ideally in the morning, after the bathroom, before eating. Don’t weigh yourself daily; it’ll just mess with your head thanks to normal body fluctuations (hormones and water retention).
At SheMed, we believe that tracking your progress shouldn’t be a guessing game, it should be built into your journey. That’s why we’ve made it part of the process.
Every week, before your GLP-1 injection, a trained proctor will check your weight and ensure it's accurately recorded. No more second-guessing the scale or wondering if you're on track. This regular check-in helps you stay accountable and gives you a consistent, reliable snapshot of your progress.
Beyond the numbers, our team also encourages you to track how you feel your energy levels, sleep, cravings, and even mood. These insights, paired with professional support, help you make adjustments early, avoid plateaus, and stay motivated throughout your transformation.
SheMed isn’t just about the medication, it's about giving you a structured, supportive system to help you succeed.
Weight alone doesn’t tell you what’s really going on. Are you losing fat but gaining muscle? A scale won’t show that. Tools like smart scales or body fat callipers can give you a clearer picture, or get a pro assessment if you want more precision.
Take measurements around your waist, hips, thighs, and arms every few weeks. Sometimes the inches drop even when the scale doesn’t budge. It’s one of the clearest signs that your body is changing for the better.
Take progress photos every week or two. Same lighting, same clothes. It might feel awkward at first, but it’s one of the most motivating ways to actually see your transformation.
Are you sleeping better? Feeling stronger on your walks? Less bloated after meals? These non-scale victories matter more than you think and they’re worth tracking, too.
If things feel confusing or you’re not sure you’re on the right track, talk to a healthcare professional. Whether it’s a GP, a dietitian, or a coach, they can give you personalised advice based on your body, goals, and lifestyle.
They’ll also keep you accountable and that’s half the battle.
At the end of the day, tracking your progress is about more than just weight loss it’s about taking charge of your health and building habits that actually stick.
Not every week will be perfect. The scale might go up before it goes down. That’s okay. What matters is that you’re moving forward and you’re doing it in a way that’s healthy, informed, and built to last.
Ready to take the first step? SheMed Healthcare’s personalised weight loss programme designed to help you track smarter and reach your goals with confidence.
1. How often should I weigh myself? Once a week is plenty. Try Monday mornings before breakfast — keep things consistent. If you are with SheMed then you’ll do it before taking the next dose with our proctor online.
2. Is the scale the only way to measure progress? Definitely not. Track how your clothes fit, take photos, and pay attention to your energy levels.
3. What if progress slows down? It happens. Reflect, adjust, and focus on how far you’ve come — not just what’s left.
Starting a new treatment can bring a mix of emotions, curiosity, hope, and sometimes a little impatience. If you've recently begun semaglutide (brand name Wegovy), you might be wondering: How soon will I notice a difference? Will my appetite change in a few days, or will it take weeks? When will I start seeing weight loss or better blood sugar control?
It’s completely natural to have these questions, especially when you’re committed to improving your health. The good news is that while semaglutide doesn’t work instantly, it does follow a clear timeline. Many people begin to notice subtle changes early on, with more significant results developing over time.
Understanding when and how semaglutide starts working can help you stay motivated and set realistic expectations. Whether you're taking it for weight loss, diabetes management, or both, knowing what to expect can make the journey smoother. Let’s explore how semaglutide works and when you might start seeing its effects.
Al Text: Semaglutide vial placed on a surface, representing a treatment for diabetes and weight management, with SheMed logo at the corner.
Semaglutide is a medication classified as a GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist) which mimics the action of the naturally occurring hormone GLP-1. This class of drugs is primarily utilised in the management of type 2 diabetes and has gained attention for its effectiveness in promoting weight loss, particularly in individuals with obesity.
Semaglutide works by enhancing insulin secretion in response to meals, inhibiting glucagon release (which raises blood glucose levels), and slowing gastric emptying. This results in better glycemic control and reduced appetite, contributing to weight loss. Semaglutide is administered via subcutaneous injection and is available in different dosages for varying therapeutic purposes.
Semaglutide was initially approved for the treatment of type 2 diabetes. Clinical studies have demonstrated its efficacy in reducing HbA1c levels (a measure of blood sugar control) and aiding weight loss among diabetic patients. For instance, a pivotal trial showed that participants using semaglutide experienced significant reductions in HbA1c levels compared to those on placebo, alongside notable weight loss.
In clinical practice, semaglutide has been shown to lead to an average weight loss of approximately 5-10% over a year when used as part of a comprehensive diabetes management plan that includes diet and exercise.
Semaglutide has been approved in the UK for long-term weight management in adults who are obese or overweight with at least one related health condition, marking a significant expansion of its use beyond diabetes treatment.
A major clinical trial involving 1,961 participants without diabetes demonstrated that those receiving semaglutide at a dose of 2.4 mg weekly achieved an average weight loss of 14.9% over 68 weeks compared to 2.4% in the placebo group. The trial also found that 86.4% of participants on semaglutide lost at least 5% of their body weight, highlighting its effectiveness as a weight loss drug.
Another landmark study assessed semaglutide's long-term effects on weight management and cardiovascular outcomes. In this trial involving over 17,000 participants with preexisting cardiovascular conditions but without diabetes, semaglutide was associated with a 15% reduction in major adverse cardiovascular events over approximately 40 months. This suggests not only its efficacy for weight management but also potential cardiovascular benefits.
Understanding the timeline of its effects is crucial for patients considering this medication.
1. Initial Weeks (Weeks 1-4): The Titration Phase
During the first four weeks of semaglutide treatment, patients typically begin a dose escalation process, also known as titration. This phase starts with a very low dose, usually 0.25 mg once weekly. The primary purpose of this low starting dose is to allow the body to gradually adjust to the medication and minimize potential side effects such as nausea, vomiting, diarrhea, or constipation, which are common gastrointestinal issues associated with GLP-1 receptor agonists. This initial dose is not considered a therapeutically effective dose for weight loss or blood sugar control, but rather an initiation dose to improve tolerability. After these initial four weeks, the dose is typically increased, assuming the patient tolerates the medication well. The full therapeutic effects are usually seen at higher maintenance doses, which are reached after a gradual escalation over several weeks to months.
2. Early Weight Loss (Weeks 4-12)
Onset of Noticeable Weight Loss
During the early phases of weight loss treatment, particularly between weeks 4 and 12, individuals often begin to notice significant changes in their body weight. Clinical studies have shown that medications such as semaglutide and tirzepatide can facilitate this process. For instance, in one study, participants receiving semaglutide experienced an average weight loss of 14.9% from baseline by week 68, while those on placebo lost only 2.4%. Similarly, tirzepatide has shown a 6.9% mean weight loss after a 12-week intensive lifestyle intervention lead-in period.
Role of Appetite Suppression and Increased Satiety
The effectiveness of these medications is largely attributed to their ability to suppress appetite and enhance feelings of satiety. Semaglutide works by mimicking GLP-1 (glucagon-like peptide-1), a hormone that regulates appetite and food intake. Participants reported improved satiety and reduced hunger levels, which contributed to their weight loss success. This appetite suppression is crucial during the initial phase as it helps individuals adhere to caloric restrictions and dietary modifications.
Potential for Modest Weight Loss
During this early phase, modest weight loss is common, with many individuals achieving at least a 5% reduction in body weight. In the SURMOUNT-3 trial, participants who added tirzepatide to their lifestyle interventions achieved an additional 21.1% mean weight loss after the initial 12 weeks. This highlights that even modest reductions can be significant when combined with behavioural changes.
As individuals progress beyond the initial weeks of treatment, they may experience a plateau in weight loss. This plateau can be frustrating but is a normal part of the weight loss journey. Studies indicate that after approximately 60 weeks, participants often see their weight loss stabilise despite ongoing treatment. Understanding this phase is essential; patience is key as the body adjusts to new weight levels.
While weight loss may slow down during this phase, continued reductions are still possible. For example, in the STEP trials involving semaglutide, participants maintained significant weight loss over two years, achieving an average reduction of 15.2% from baseline by week 104. This suggests that while the rate of loss may decrease, sustained efforts can still yield positive outcomes.
Importance of Lifestyle Modifications
To maximise results during the sustained weight loss phase, lifestyle modifications remain critical. A combination of dietary changes and regular physical activity is recommended. In clinical trials, participants were encouraged to maintain a caloric deficit through diet and engage in at least 150 minutes of physical activity per week. These behavioural strategies not only support continued weight loss but also contribute to overall health improvements.
Individual responses to semaglutide can vary significantly due to genetic and metabolic factors. Genetic polymorphisms can influence how individuals metabolise medications, affecting their efficacy and side effects. For instance, variations in genes related to drug metabolism, such as CYP450 enzymes, can lead to differences in drug clearance rates and effectiveness. A study indicated that genetic factors could account for approximately 30% of the variability in weight loss outcomes among participants treated with semaglutide.
Additionally, metabolic rates vary between individuals; those with a higher basal metabolic rate (BMR) may experience more significant weight loss than those with a lower BMR. This variability underscores the importance of personalised approaches in obesity treatment.
Clinical studies have shown that while semaglutide is effective for many, results can differ widely among individuals. For example, in the STEP 1 trial involving 1,961 participants, the mean weight loss after 68 weeks was 14.9% for those on semaglutide, but some participants lost significantly more or less weight. This variability can be attributed to factors such as adherence to treatment, lifestyle changes, and individual physiological differences.
Adherence to semaglutide treatment is crucial for achieving optimal weight loss results. Studies have demonstrated that consistent use of the medication leads to better outcomes. For instance, participants who adhered strictly to their treatment regimen were more likely to achieve significant weight loss compared to those who missed doses.
Missed doses can severely impact the efficacy of semaglutide. A study showed that participants who missed doses experienced a 50% reduction in the expected weight loss compared to those who maintained their dosing schedule. This highlights the necessity for patients to understand the importance of regular administration and its role in achieving their weight loss goals.
Lifestyle modifications play a vital role in enhancing the effectiveness of semaglutide for weight loss. A healthy diet rich in whole foods, combined with regular physical activity, has been shown to significantly improve outcomes. In the STEP trials, participants who engaged in structured lifestyle interventions alongside semaglutide treatment lost an average of 15.3 kg over 68 weeks compared to just 2.6 kg in the placebo group.
Research indicates that lifestyle changes can amplify the effects of semaglutide. For example, incorporating at least 150 minutes of moderate-intensity exercise per week along with dietary changes can lead to improved metabolic health and greater reductions in body weight. A study found that participants who followed both medication and lifestyle recommendations achieved greater improvements not only in weight but also in cardiovascular risk factors such as blood pressure and cholesterol levels.
Semaglutide has garnered significant attention for its dual role in managing type 2 diabetes and promoting weight loss. It is crucial for individuals considering or currently undergoing treatment with semaglutide to consult with healthcare professionals for personalised advice tailored to their unique circumstances. This guidance can help optimise treatment effectiveness and address any concerns regarding side effects or interactions with other medications.
Moreover, a holistic approach to weight management is essential. Combining medication with lifestyle changes, such as adopting a healthy diet and engaging in regular physical activity, can significantly enhance weight loss outcomes. Studies indicate that those who incorporate behavioural modifications alongside semaglutide treatment experience better results than those relying solely on medication.
Need personalised guidance? Our expert team is here to support you. Contact us at SheMed today for tailored advice and solutions that fit your needs. Let’s take the next step toward your health and well-being together!
Frequently Asked Question
A groundbreaking study published in The Lancet’s eClinicalMedicine has found that first-generation GLP-1 receptor agonists (GLP-1RAs), such as liraglutide and exenatide, reduce the risk of obesity-related cancers by 41% compared to bariatric surgery-even after accounting for differences in weight loss. The findings, presented at the European Congress on Obesity (ECO 2025), challenge assumptions about how these medications protect against cancer and highlight their potential beyond metabolic benefits.
Researchers from Clalit Health Services (Israel) compared patients treated with GLP-1RAs (≥6 monthly prescriptions of liraglutide, exenatide, or dulaglutide) to those who underwent bariatric surgery between 2010–2018. Over a median 7.5-year follow-up, 298 participants developed obesity-related cancers, with postmenopausal breast cancer (26%), colorectal cancer (16%), and endometrial cancer (15%) most prevalent.
Obesity and diabetes are linked to 40% of cancers, but this study suggests GLP-1 medications could disrupt that trajectory. “Weight loss alone doesn’t fully explain the anti-cancer benefits,” said lead author Dr. Yael Wolff Sagy. Co-author Dr. Dror Dicker emphasized the role of inflammation reduction, noting, “GLP-1RAs likely act through multiple pathways to suppress tumor growth.”
Professor Naveed Sattar (University of Glasgow), uninvolved in the study, cautioned that observational data cannot prove causation but called the results “intriguing.” Professor Mark Lawler (Queen’s University Belfast) hailed the findings as “transformational,” suggesting GLP-1 drugs could halve obesity-related cancer risk compared to surgery’s one-third reduction.SheMed welcomes this important research and is committed to keeping our community informed about advances in women’s health and weight management. We’ll continue to share updates on new studies like this, helping you make empowered, evidence-based decisions on your health journey.
The SheMed Weight Loss Programme is a female-focused, clinically supervised service designed to support women on their weight loss journey with safety and personalisation at its core. Every participant begins with a comprehensive blood test, ensuring the programme is tailored to their unique health needs and that safety is prioritised from the start. SheMed’s approach includes regular clinical oversight, monthly reviews, and ongoing support, including symptom management and educational resources. Members benefit from progress tracking, weekly check-ins, and a supportive community, all aimed at empowering women to achieve lasting, meaningful results.
Women’s Health and SheMed SheMed’s commitment to advancing women’s health goes beyond weight loss. In December 2024, SheMed launched an active clinical study to explore how GLP-1 weight loss medications may benefit conditions that disproportionately affect women, such as PCOS, endometriosis, and menopause symptoms. This research addresses the significant gap in women’s health studies-currently, only 1% of UK healthcare research funding is dedicated to female-specific conditions. The SheMed study aims to generate actionable insights on how weight loss treatments can improve not just weight, but also broader aspects of women’s health, helping to shape future care and treatment approaches.
References
.svg)
